Cimon Medical
A New Benchmark in Continuous Blood Flow Monitoring

Unstable cerebral blood flow (CBF) is common among critically ill, preterm infants in neonatal intensive care units (NICU). Every year, an estimated 18 percent of premature babies risk developing brain damage due to unstable CBF. Current monitoring and management are based on the interpretation of indirect markers of systemic perfusions, such as heart rate, blood pressure, urine output, blood gas analysis, and capillary refill time. It’s a costly and time-consuming approach that still yields no more than an estimate.

Cimon Medical, an emerging medtech company, is solving this clinical need with their proprietary technology for continuous monitoring of blood flow using non-invasive doppler ultrasound. Their coin-size ultrasound probe is constructed as a single element transducer with a wide beam to continuously measure blood circulation by illuminating a 1×4cm cylindric area of tissue.

“This is a critical innovation for two reasons. A single element transducer with a central circular aperture has a larger effective area than an array transducer with a rectangular aperture, generating better lateral image resolution while being more compact and affordable. The next advantage is simultaneously capturing all blood flow signals in a targeted area to help clinicians provide a near-immediate response for adverse events, which was previously not possible,” says Jerome Marzinski, interim CEO and board member, Cimon Medical.

Cimon Medical’s first step towards achieving this medical breakthrough is NeoDoppler, a device designed to continuously and non-invasively monitor the CBF of premature or critically ill babies. Cimon Medical is optimistic that NeoDoppler will be CE-marked under the European Union’s Medical Device Regulation (MDR) by the fourth quarter of 2022. They plan to market it in Scandinavia, Germany, France, and Spain, through centres of excellence.

Applications beyond a Bedside Blood Flow Monitor

NeoDoppler is just the tip of the iceberg. The company’s next step is using doppler ultrasound technology to extend the capabilities for cardiac surgeries or interventions inside and outside a hospital setting. During cardiac surgery, if an air bubble is introduced into a patient’s blood circulation, it can cause blood vessel blockages and clots, leading to a stroke. Its timely monitoring can help a surgeon quickly strategise and take the right action to remedy the situation. Cimon Medical is developing new probes towards this type of clinical application. By aiding clinicians in monitoring blood flow during cardiac surgery, it can reduce or avert clinical endpoints leading to blood vessel blockages.

“Our goal through these applications of doppler ultrasound is to become a market leader in continuous blood flow monitoring. We aim to address diverse use cases, from a critical newborn in the NICU to cardiac surgery and intervention. We will soon add more applications to help clinicians make timely, cost-effective, and accurate clinical decisions for the better sake of the patient,” states Marzinski.

Rising Market Acceptance of the Novel Technology

Cimon Medical is already receiving effective traction from the Nordic region’s top-notch research centres and universities for including NeoDoppler in their clinical settings. The company wants to leverage these early adopters to evangelise the healthcare market, while showcasing NeoDoppler’s clinical evidence to identify hemodynamic instability.

Our goal through these applications of doppler ultrasound is to become a market leader in continuous blood flow monitoring. We aim to address diverse use cases, from a critical newborn in the NICU to cardiac surgery and intervention

The company is also planning a multi-centre pivotal study to provide more compelling clinical evidence from a clinician’s standpoint. The multi-centre study would aim to conduct comparative effectiveness research to promote its technology’s advantage over a predicate being identified as a non-invasive method of measuring blood flow, near infrared spectroscopy (NIRS).



Since NIRS is a measurement of brain tissue oxygenation, it may not fully explain blood flow and hemodynamic instability like Cimon Medical’s device. Even if it does, NIRS provides an indirect estimate of CBF and cannot detect real-time fluctuation in circulation, like NeoDoppler. That makes Cimon Medical’s offering unique and breakthrough from a clinical endpoint perspective.

A Technology Backed by Sound Clinical and Business Experts

One of the biggest hurdles to any medtech startup’s journey today is bringing superior technology to the market with the lowest possible capital investment. Cimon Medical efficiently jumps the hurdle because its talented team has diverse clinical, technology, and business expertise. Marzinski, for instance, has been a C-level executive for many medtech and life sciences companies in the past, with market knowledge in ophthalmology, interventional neuroradiology, interventional cardiology, robotic surgery, molecular diagnostics. He is also a strategic advisor, providing management consulting services to medical device companies on how to successfully launch products or expand footprints. He is not on an uncharted road when it comes to building high-performing teams or strategies that deliver superior value. Strong, deeply knowledgeable leadership is a major differentiator for the company. Their vast practical experience results in more productive yields with less capital.

The company is backed by strong investors with two lead investors: Proventure and Investinor from Norway. They trust in the company’s competency when it comes to ground-breaking clinical applications. With their continued support, Cimon Medical intends to reach new levels of innovation in continuous blood flow monitoring for developing new standards of care.